Itraconazole: Difference between revisions
(Replace manual dosing with dynamic SMW tables (Adult + Pediatric)) |
(Restore original dosing content alongside dynamic SMW tables) |
||
| Line 6: | Line 6: | ||
==Adult Dosing== | ==Adult Dosing== | ||
*200mg PO 1-4 times per day | |||
===Indications by Disease=== | ===Indications by Disease=== | ||
{{#ask: [[Has DrugName::Itraconazole]] [[Has Population::Adult]] | {{#ask: [[Has DrugName::Itraconazole]] [[Has Population::Adult]] | ||
|?Treats disease=Disease | |?Treats disease=Disease | ||
|?Has Dose=Dose | |?Has Dose=Dose | ||
|?Has Context=Context | |?Has Context=Context | ||
|format=table | |format=table | ||
|limit=50 | |limit=50 | ||
|mainlabel=- | |mainlabel=- | ||
|headers=show | |headers=show | ||
|sort=Treats disease | |sort=Treats disease | ||
}} | }} | ||
==Pediatric Dosing== | ==Pediatric Dosing== | ||
*> 5y: 2.5-10mg/kg 2-3 times per day | |||
===Indications by Disease=== | ===Indications by Disease=== | ||
{{#ask: [[Has DrugName::Itraconazole]] [[Has Population::Pediatric]] | {{#ask: [[Has DrugName::Itraconazole]] [[Has Population::Pediatric]] | ||
|?Treats disease=Disease | |?Treats disease=Disease | ||
|?Has Dose=Dose | |?Has Dose=Dose | ||
|?Has Context=Context | |?Has Context=Context | ||
|format=table | |format=table | ||
|limit=50 | |limit=50 | ||
|mainlabel=- | |mainlabel=- | ||
|headers=show | |headers=show | ||
|sort=Treats disease | |sort=Treats disease | ||
}} | }} | ||
Latest revision as of 02:38, 20 March 2026
Administration
- Type: Antifungal
- Dosage Forms: Capsule, solution (for oropharyngeal/esophageal candida)
- Routes of Administration:
- Common Trade Names: Sporanox, Sporaz, Orungal
Adult Dosing
- 200mg PO 1-4 times per day
Indications by Disease
| Disease | Dose | Context |
|---|---|---|
| Cryptococcosis | 200mg PO q12hrs x 6-12 months | Pulmonary not AIDS associated alt |
Pediatric Dosing
- > 5y: 2.5-10mg/kg 2-3 times per day
Indications by Disease
| Disease | Dose | Context |
|---|---|---|
| Tinea capitis | 3-5mg/kg PO daily (max 400mg) x 4-6 weeks | Second line |
Special Populations
- Pregnancy Rating: C
- Lactation risk: Infant risk cannot be ruled out
Renal Dosing
- Adult: No adjustment
- Pediatric:
Hepatic Dosing
- Adult: No adjustment
- Pediatric:
Contraindications
- Allergy to class/drug
- Concomitant use of CYP3A4 substrates (e.g. ergots, lurasidone, methadone, oral midazolam, simvastatin, ticagrelor, and triazolam)
- Ventricular dysfunction (relative)
Adverse Reactions
Serious
- CHF, pulmonary edema
- Hepatotoxicity
- SJS/TEN
- Pancreatitis
Common
- Nausea/vomiting, diarrhea, abdominal pain
- Headache, dizziness
- Edema
- Pruritus, rash
- URI symptoms
Pharmacology
- Half-life: 32-96h
- Metabolism: Hepatic, P450 CYP3A4
- Excretion: Urine, Feces
Mechanism of Action
- Inhibits synthesis of ergosterol (fungal cell membrane component)